One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Oxaliplatin Plus LV5FU2 in Colorectal Cancer.
Mayer, Robert J. MD 1,2,,
doi : 10.1200/JCO.23.01109
Volume 41(33) pgs. 5077-5205 November 20, 2023
JCO Flashback: Exploring an Effective Drug Combination for Colorectal Cancer (2000).
doi : 10.1200/JCO.23.01344
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer.
de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C.; Hendler, D.; de Braud, F.; Wilson, C.; Morvan, F.; Bonetti, A.
doi : 10.1200/JCO.22.02773
Too Much, Too Little, or Just Right? Obesity and Dosing of Targeted Therapies in Breast Cancer.
Cao, Chao PhD, MPH 1; Ligibel, Jennifer A. MD 1,
doi : 10.1200/JCO.23.01516
Sexual and Gender Minority Invisibility in Cancer Studies: A Call for Effective Recruitment Methods to Address Cancer Disparities.
Rosser, B.R. Simon MPH, PhD 1,,; Weideman, Ben C.D. MS 1; Rider, G. Nic PhD 2; Jatoi, Aminah MD 3; Ecklund, Alexandra M. MPH 1; Wheldon, Christopher W. PhD 4; Talley, Kristine M.C. CNP, RN, PhD 5; Kulasingam, Shalini MPH, PhD 1; Smith, M. Kumi PhD 1; Jacobs, David R. PhD 1; Mitteldorf, Darryl MSW, MPA 6; West, William PhD 7; Alley, Rhea BA 1; Ross, Michael W. MD, PhD 2
doi : 10.1200/JCO.23.00655
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Dimopoulos, Meletios A. MD 1,,; Opat, Stephen MBBS 2,; D'Sa, Shirley MD 3,; Jurczak, Wojciech MD 4,; Lee, Hui-Peng MBChB 5,; Cull, Gavin MBBS 6,; Owen, Roger G. MD 7,; Marlton, Paula MBBS 8,; Wahlin, Bjorn E. MD, PhD 9,; Garcia-Sanz, Ramon MD, PhD 10,; McCarthy, Helen MD 11,; Mulligan, Stephen PhD, MBBS 12,; Tedeschi, Alessandra MD 13,; Castillo, Jorge J. MD 14,; Czyz, Jaroslaw MD, PhD 15; Fernandez de Larrea, Carlos MD, PhD 16,; Belada, David PhD 17,; Libby, Edward MD 18,; Matous, Jeffrey MD 19,; Motta, Marina MD 20; Siddiqi, Tanya MD 21,; Tani, Monica MD 22,; Trneny, Marek MD 23,; Minnema, Monique C. MD, PhD 24,; Buske, Christian MD 25,; Leblond, Veronique MD, PhD 26,; Treon, Steven P. MD, PhD 14,; Trotman, Judith MBChB 27,; Chan, Wai Y. PhD 28,; Schneider, Jingjing PhD 28,; Allewelt, Heather MD 28,; Patel, Sheel PharmD 28,; Cohen, Aileen MD 28,; Tam, Constantine S. MD 2,29,
doi : 10.1200/JCO.22.02830
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Zinzani, Pier Luigi MD, PhD 1,,; Mayer, Jiri MD 2,; Flowers, Christopher R. MD, MS, FASCO 3,; Bijou, Fontanet MD 4; De Oliveira, Ana C. MD, PhD 5,; Song, Yuqin MD, PhD 6; Zhang, Qingyuan MD, PhD 7; Merli, Michele MD 8,; Bouabdallah, Krimo MD 9,; Ganly, Peter BMBCh, PhD, FRACP FRCPA 10; Zhang, Huilai MD, PhD 11; Johnson, Roderick MD 12,; Martin Garcia-Sancho, Alejandro MD, PhD 13,; Provencio Pulla, Mariano MD, PhD 14,; Trneny, Marek MD 15,; Yuen, Sam MBBS, FRACP, FRCPA 16; Tilly, Herve MD, PhD 17,; Kingsley, Edwin MD 18; Tumyan, Gayane MD, PhD 19; Assouline, Sarit E. MD, MSc, FRCPC 20,; Auer, Rebecca MRCP, FRCPath, PhD 21,; Ivanova, Elena PhD 22,; Kim, Pil PhD 23,; Huang, Sha MD 24,; Delarue, Richard MD 22,; Trotman, Judith MBChB, FRACP, FRCPA 25,
doi : 10.1200/JCO.23.00775
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Pfeiler, Georg MD 1,,; Hlauschek, Dominik MSc 2,; Mayer, Erica L. MD, MPH 3,; Deutschmann, Christine MD 1,; Kacerovsky-Strobl, Stephanie MD 4; Martin, Miguel MD 5,; Meisel, Jane Lowe MD 6,; Zdenkowski, Nicholas MD 7,; Loibl, Sibylle MD 8,9,10,; Balic, Marija MD 11,; Park, Haeseong MD 12,; Prat, Aleix MD 13,; Isaacs, Claudine MD 14,; Bajetta, Emilio MD 15,16; Balko, Justin M. MD 17,; Bellet-Ezquerra, Merixtell MD 18,; Bliss, Judith MSc 19,; Burstein, Harold MD 20; Cardoso, Fatima MD 21,; Fohler, Hannes MVM 2,; Foukakis, Theodoros MD 22,23,; Gelmon, Karen A. MD 24,; Goetz, Matthew MD 25,; Haddad, Tufia C. MD 26,; Iwata, Hiroji MD 27,; Jassem, Jacek MD 28,; Lee, Soo-Chin MD 29,30,31,; Linderholm, Barbro MD 32,33,; Los, Maartje MD 34; Mamounas, Eleftherios P. MD 35,; Miller, Kathy D. MD 36,; Morris, Patrick G. MD 37,38,; Munzone, Elisabetta MD 39,; Gal-Yam, Einav Nili MD 40,; Ring, Alistair MD 41,; Shepherd, Lois MD 42; Singer, Christian MD 1,43,; Thomssen, Christoph MD 44,; Tseng, Ling-Ming MD 45; Valagussa, Pinuccia MD 46; Winer, Eric P. MD 47,; Wolff, Antonio C. MD 48,; Zoppoli, Gabriele MD 49,50,; Machacek-Link, Jana PhD 2,; Schurmans, Celine MSc 51,; Huang, Xin MSc 52,; Gauthier, Eric PhD 52,; Fesl, Christian PhD 2,; Dueck, Amylou C. PhD 53; DeMichele, Angela MD 54,; Gnant, Michael MD, FACS 2,43,; on behalf of the PALLAS Groups and Investigators; for the PORTEC Study Group; Cameron, David; El-Abed, Sarra; Rugo, Hope S.; Steger, Guenther G.; Traina, Tiffany; Werutsky, Gustavo; Wolmark, Norman
doi : 10.1200/JCO.23.00126
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas, Richard MD 1,,; Rothschild, Sacha I. MD, PhD 2,3,; Hayoz, Stefanie PhD 4; Bubendorf, Lukas MD 5,; Ozdemir, Berna C. MD 6,; Kiss, Bernhard MD, PhD 7,; Erdmann, Andreas MD 8; Aeppli, Stefanie MD 9,; Mach, Nicolas MD 10,; Strebel, Rato T. MD 11; Hadaschik, Boris MD 12,; Berthold, Dominik MD 13,; John, Hubert MD 14,; Zihler, Deborah MD 15,; Schmid, Mathias MD 16; Alborelli, Ilaria PhD 5,; Schneider, Martina PhD 4; Musilova, Jana PhD 4; Spahn, Martin MD 1,7,18,; Petrausch, Ulf MD 19,
doi : 10.1200/JCO.23.00363
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Duvivier, Herbert L. MD 1,; Rothe, Michael MS 2; Mangat, Pam K. MS 2,; Garrett-Mayer, Elizabeth PhD 2; Ahn, Eugene R. MD 3; Al Baghdadi, Tareq MD 4,; Alva, Ajjai S. MBBS, MS 5,; Dublis, Stephanie A. DO 6; Cannon, Timothy L. MD 7,; Calfa, Carmen J. MD 8; Li, Rui MD, PhD 9,; Behl, Deepti MD 10,; Chiu, Vi K. MD, PhD 11,; Gold, Philip J. MD 12; Marr, Alissa S. MD 13; Mileham, Kathryn F. MD 14,; Powell, Steven Francis MD 15,; Rodon, Jordi MD 16,; Thota, Ramya MBBS 17; Grantham, Gina N. BS 2; Gregory, Abigail BS, MPH 2,; Hinshaw, Dominique C. PhD 2; Halabi, Susan PhD, FASCO, FASA, FCST 18,; Schilsky, Richard L. MD, FACP, FSCT, FASCO 2,
doi : 10.1200/JCO.23.00702
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
Mandelker, Diana MD, PhD 1; Marra, Antonio MD 1; Zheng-Lin, Binbin MD 2; Selenica, Pier BSc 1; Blanco-Heredia, Juan PhD 1; Zhu, Yingjie MD 1; Gazzo, Andrea PhD 1,; Wong, Donna MS 1; Yelskaya, Zarina MA 1; Rai, Vikas MS 1; Somar, Joshua MS 1; Ostafi, Silvana BA 1,; Mehta, Nikita MS 1,; Yang, Ciyu PhD 1; Li, Yirong PhD 1; Brown, David N. PhD 1; da Silva, Edaise M. PhD 1; Pei, Xin PhD 3; Linkov, Irina PhD 1; Terraf, Panieh PhD 1; Misyura, Maksym PhD 1; Ceyhan-Birsoy, Ozge PhD 1; Ladanyi, Marc MD 1,; Berger, Michael PhD 1,; Pareja, Fresia MD, PhD 1; Stadler, Zsofia MD 4,; Offit, Kenneth MD, MPH 4,; Riaz, Nadeem MD 3,; Park, Wungki MD 2,; Chou, Joanne MPH 5,; Capanu, Marinela PhD 5; Koehler, Maria MD, PhD 6,; Rosen, Ezra MD, PhD 4; O'Reilly, Eileen M. MD 2,7,8,; Reis-Filho, Jorge S. MD, PhD 1,,
doi : 10.1200/JCO.23.00561
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
Qin, Shukui MD 1,; Li, Jin MD 2; Bai, Yuxian MD, PhD 3; Wang, Zishu MD 4; Chen, Zhendong MD, PhD 5; Xu, Ruihua MD, PhD 6,; Xu, Jianming MD 7; Zhang, Hongmei MD 8; Chen, Jia MD 9; Yuan, Ying MD 10; Liu, Tianshu MD 11; Yang, Lin MD, PhD 12; Zhong, Haijun MD 13; Chen, Donghui MD 14; Shen, Lin MD, PhD 15,; Hao, Chunyi MD, PhD 15; Fu, Deliang MD, PhD 16; Cheng, Ying MD 17; Yang, Jianwei MD 18; Wang, Qiong MD 19; Qin, Baoli MD 20; Pan, Hongming MD 21; Zhang, Jun MD, PhD 22; Bai, Xianhong MD 23,; Zheng, Qingshan MD, PhD 24
doi : 10.1200/JCO.22.02630
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
Hargrave, Darren R. MD, MBChB, MRCP, FRCPCH 1,; Terashima, Keita MD, PhD 2; Hara, Junichi MD, PhD 3; Kordes, Uwe R. MD 4; Upadhyaya, Santhosh A. MD 5; Sahm, Felix MD, PhD, MBA 6,7,8; Bouffet, Eric MD 9; Packer, Roger J. MD 10; Witt, Olaf MD 8; Sandalic, Larissa MSc 11; Kieloch, Agnieszka MSc 12; Russo, Mark MD, PhD 13; Cohen, Kenneth J. MD, MBA 14; the Investigators involved in the high-grade glioma cohort; the Investigators involved in the high-grade glioma cohort; Diez, Blanca; Cappellano, Andrea; Epelman, Sidnei; Mancano, Bruna; Nysom, Karsten; Aerts, Isabelle; Bertozzi, Anne-Isabelle; Witt, Olaf; Kramm, Christof; Fleischhack, Gudrun; Kordes, Uwe; Hernaiz-Driever, Pablo; Massimino, Maura; Garre, Maria Luisa; Locatelli, Franco; Terashima, Keita; Okada, Keiko; Koga, Yuki; Van der Lugt, Jasper; Maschan, Alexey; Lassaletta, Alvaro; Holm, Stefan; Hargrave, Darren; Howell, Lisa; Upadhyaya, Santhosh; Gauvain, Karen; Cohen, Kenneth; Baxter, Patricia
doi : 10.1200/JCO.23.00558
Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.
Singer, Eric A. MD, MA, MS 1,; Rumble, R. Bryan MSc 2; Rathmell, W. Kimryn MD, PhD 3,; Van Veldhuizen, Peter J. MD 4; for the Management of Metastatic Renal Clear Cell Cancer Guideline Expert Panel; Management of Metastatic Renal Clear Cell Cancer Guideline Expert Panel; Kimryn Rathmell, W.; Van Veldhuizen, Peter J.; Bryan Rumble, R.; Al-Ahmadie, Hikmat; Emamekhoo, Hamid; Hauke, Ralph J.; Louie, Alexander V.; Milowsky, Matthew I.; Molina, Ana M.; Rose, Tracy L.; Siva, Shankar; Zaorsky, Nicholas G.; Zhang, Tian; Qamar, Rubina; Kungel, Terry M.; Lewis, Bryan; Singer, Eric A.
doi : 10.1200/JCO.23.01977
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen, Patrick Y. MD 1,,; van den Bent, Martin MD 2,; Youssef, Gilbert MD 1; Cloughesy, Timothy F. MD 3,; Ellingson, Benjamin M. PhD 4,; Weller, Michael MD 5,; Galanis, Evanthia MD 6,; Barboriak, Daniel P. MD 7,; de Groot, John MD 8,; Gilbert, Mark R. MD 9; Huang, Raymond MD, PhD 10,; Lassman, Andrew B. MD 11,; Mehta, Minesh MD 12,; Molinaro, Annette M. PhD 13; Preusser, Matthias MD 14,; Rahman, Rifaquat MD 15,; Shankar, Lalitha K. MD, PhD 16; Stupp, Roger MD 17,; Villanueva-Meyer, Javier E. MD 18,; Wick, Wolfgang MD 19,; Macdonald, David R. MD 20,; Reardon, David A. MD 1,; Vogelbaum, Michael A. MD, PhD 21,; Chang, Susan M. MD 8,
doi : 10.1200/JCO.23.01059
Premonition of Death.
Bramati, Patricia S. MD 1,; Aldana, Grecia MD 1; Bruera, Eduardo MD 1,
doi : 10.1200/JCO.23.01269
Surgery in Metastatic Seminoma: Negative Trial Should Be Treated as Negative.
Rumyantsev, Alexey A. MD, PhD; Tyulyandina, Alexandra S. MD, PhD; Tryakin, Alexey A. MD, PhD; Fedyanin, Mikhail Y. MD, PhD; Tjulandin, Sergey A. MD, PhD
doi : 10.1200/JCO.23.00629
Reply to A. Rumyantsev et al.
Daneshmand, Siamak MD; Hu, Brian MD; Nichols, Craig MD
doi : 10.1200/JCO.23.01148
Erratum: Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
doi : 10.1200/JCO.23.02063
